Despite a resurgence of flavivirus infections worldwide, no approved therapeutic agent exists for any member of the genus. While cross-reactive antibodies with therapeutic potential against flaviviruses have been generated, the majority of them are anti-E antibodies with the potential to cause antibody-dependent enhancement of flavivirus infection and disease. We described previously mAbs against the non-structural NS1 protein of the West Nile virus (WNV) that were protective in mice when administered pre-or post-infection of WNV. Here, we demonstrate that one of these mAbs (16NS1) cross-reacted with Japanese encephalitis virus (JEV) and exhibited protective activity against a lethal JEV infection. Overlapping peptide mapping analysis combined with site-specific mutations identified a novel epitope 116 KAWGKSILFA 125 and critical amino acid residues ( 118 W and 122 I) for 16NS1 mAb binding. These results may facilitate the development of a broadly therapeutic mAb that lacks enhancing potential and/or subunit-based vaccine against flaviviruses that target the NS1 protein.
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Mosquito-borne flaviviruses such as dengue (DENV), Japanese encephalitis (JEV), West Nile (WNV), yellow fever (YFV) and St. Louis encephalitis (SLEV) viruses are important human pathogens that cause severe haemorrhagic or encephalitic diseases worldwide (Gould & Solomon, 2008; Hubálek & Halouzka, 1999; Mackenzie et al., 2004; Petersen et al., 2003; Rodenhuis-Zybert et al., 2011) . In recent decades, flaviviruses have spread into new geographical areas exemplified by the spread of WNV in North America and JEV through much of Asia and Oceania (Jia et al., 1999; Lanciotti et al., 1999 Lanciotti et al., , 2002 Mackenzie et al., 2002a, b; Petersen et al., 2003) . The co-circulation of these flaviviruses (e.g. DENV, JEV and YFV) also occurs in endemic areas (Douglas et al., 2007; Jupp, 2001; Mackenzie et al., 2004) . At present, no specific therapy for flavivirus diseases is approved for use in humans.
Several groups have generated protective mAbs against the flavivirus structural E protein and the non-structural NS1 proteins (Chung et al., 2006b (Chung et al., , 2007 Crill & Roehrig, 2001; Desprès et al., 1991; Gould et al., 1986; Henchal et al., 1988; Oliphant et al., 2005; Schlesinger et al., 1985 Schlesinger et al., , 1993 SukupolviPetty et al., 2007) . Indeed, anti-E protein neutralizing mouse and human antibodies with prophylactic and therapeutic capacity have been developed (Balsitis et al., 2010; Oliphant et al., 2005; Roehrig et al., 2001; Shrestha et al., 2010; Sukupolvi-Petty et al., 2010) . Some of these neutralizing mAbs have broad cross-reactivity with flaviviruses and their protective mechanisms and specific-binding sites have been characterized (Beasley & Aaskov, 2001; Crill & Chang, 2004; Deng et al., 2011; Serafin & Aaskov, 2001; Shrestha et al., 2010) . Although these studies suggest that anti-E mAb-based therapy could be a promising strategy to control flavivirus infections, subneutralizing concentrations of anti-E antibody have the potential to cause antibody-dependent enhancement (ADE) of flavivirus infections that could complicate the antibody therapy (Cardosa et al., 1986; Mehlhop et al., 2007; Peiris et al., 1981; Pierson et al., 2007) . As an alternative target, the NS1 protein induces non-neutralizing protective antibodies, and some of these antibodies elicit protective immunity through Fc-c receptor-dependent effector pathways (Chung et al., 2007; Schlesinger et al., 1993) . Although the epitopes of a few mAbs against flavivirus NS1 have been localized (Chung et al., 2006b; Falconar et al., 1994; Henchal et al., 1987; Putnak et al., 1988; Young, 1990) , no NS1 mAb with a cross-protective effect against flavivirus infections has been mapped to specific amino acids or structural determinants.
Previously, we generated and characterized 22 mAbs against WNV NS1, a secreted glycoprotein in flaviviruses that is absent from the virion and thus, is not associated with ADE (Chung et al., 2006b) . To define broadly protective anti-NS1 mAbs against flaviviruses, we evaluated the cross-reactivity of anti-WNV NS1 mAbs using flow cytometry with BHK21 cells infected with JEV strain K87P39, isolated in Korea ( (Chung et al., 2006b) . These results suggest that the 16NS1 mAb recognized a linear or heat-stable epitope under SDS-PAGE conditions. In addition, 16NS1 mAb detected monomeric and oligomeric forms of NS1 in JEV-infected BHK21 cells, which also have been observed for other flavivirus NS1 proteins ( Fig. 1c ) (Blitvich et al., 1999; Mason, 1989; Melian et al., 2010; Youn et al., 2010) . On SDS-PAGE analysis with boiled samples prior to electrophoresis, the 16NS1 mAb recognized monomeric forms of the NS1 protein with two different molecular masses (designated NS1 and NS19) at~42 and~53 kDa, respectively. The 16NS1 mAb also identified more than four discrete bands that might have originated from homo-and hetero-multimers of NS1 and NS19 after SDS-PAGE of nonheated antigen in JEV-infected BHK21 cells. Taken together, 10 of the 22 anti-WNV NS1 mAbs cross-reacted with JEV, with the 16NS1 mAb recognizing different forms of NS1 in lysates from infected BHK21 cells or a bacteria expressing recombinant fragment of NS1.
As the cross-reactive mAb 16NS1 showed a strong therapeutic effect against WNV infection (Chung et al., 2006b) , we assessed its prophylactic activity in a mouse model of lethal JEV (K87P39 strain) infection. Studies were performed with 6-week-old ICR mice that have an approximately 40 % survival rate against lethal JEV infection. Mice were inoculated intramuscularly with 10 2 p.f.u. of JEV and were administered intraperitoneally a single dose of purified mAb (500 mg) at the same time. Notably, one dose of 16NS1 mAb significantly enhanced the survival rate of mice after lethal JEV infection to 95 %, compared with saline-treated control (P50.0001, n520, Fig. 1d ). These results suggest that 16NS1 mAb effectively protected mice against lethal JEV infection. As expected, 16NS1 did not show any inhibitory effect on JEV and WNV infection in BHK21 cell culture using a plaque reduction assay (data not shown). However, 16NS1 mAb did not show any therapeutic activity against lethal JEV infection when administered at day 2 after infection (data not shown) 
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I + *Data adapted from Chung et al. (2006b Chung et al. ( , 2007 and administration of 3NS1 did not protect JEV-infected mouse in contrast to WNV infection ( Fig. 1d) (Chung et al., 2006b) . The differential inhibitory activity of 3NS1 and 16NS1 against JEV infection might result from different functions of NS1 proteins between flaviviruses for pathogenesis and interactions with host factors. In support of this, DENV and JEV NS1 proteins show differential binding to uninfected cells and expression on the surface of infected cells (Avirutnan et al., 2007; Krishna et al., 2009; Youn et al., 2010) , and WNV NS1 attenuates the alternative pathway of complement activation by binding factor H in contrast to JEV NS1 (Chung et al., 2006a; Krishna et al., 2009) . Alternatively, 3NS1 and 16NS1 could bind with lower affinity to JEV compared with WNV NS1, which would impact therapeutic efficacy. Although follow-up studies on the detailed mechanisms underlying the protection of 16NS1 with JEV are needed, given that this mAb recognized cell surface-associated NS1 on JEV-infected cells (data not shown), it likely facilitates phagocytosis and clearance of JEV-infected cells through Fc-c receptors, as has been observed with WNV infection (Chung et al., 2007) .
Mapping of protective mAbs may provide useful information for developing effective therapies and optimized vaccines against flavivirus infections. Indeed, recent studies have identified contact residues to neutralizing mAbs against flavivirus E protein by analysing neutralization escape mutants, displaying variant E proteins on yeast surface, and by co-crystallography of E proteins with the Fab fragments of neutralizing mAbs (Beasley & Barrett, 2002; Lok et al., 2008; Nybakken et al., 2005; Oliphant et al., 2005; Shrestha et al., 2010) . Unfortunately, most protective mAbs against flavivirus NS1 are uncharacterized from a structural standpoint. Since the 16NS1 mAb recognized a bacterially derived fragment through Western blotting after heat treatment (Fig. 1b) , we hypothesized that it recognized a linear peptide on NS1. As such, we determined its epitope using ELISA and synthetic peptides derived from the entire NS1 protein of WNV (New York 1999 strain) that was previously used as the antigen for anti-WNV mAbs (Chung et al., 2006b 4) and JEV-infected BHK21 cells (lanes 2 and 3) were separated by non-reducing SDS-PAGE (10 % Tris-glycine gel) after incubation at 95 6C (lanes 1 and 2) or room temperature (lanes 3 and 4) for 3 min, and subjected to Western blot analysis using 16NS1 mAb. Arrows and 'Multimers' designate the monomeric (NS1 and NS19) and multimeric forms of NS1, respectively. The position of protein size markers (in kDa) is indicated at the left of the gel. (d) Protective efficiency of 16NS1 mAb in JEV-infected mice. Six-week-old ICR mice were infected intramuscularly with 10 2 p.f.u. of JEV and administrated intraperitoneally a single dose of purified mAbs (500 mg) at the same time. The statistical difference in survival curves was significant between PBS and 16NS1 mAb treatments (n520, P50.0001), but not between PBS and 3NS1. The survival curves were constructed from at least two independent experiments and analysed by the log-rank test.
the Escherichia coli-expressed FR-I of WNV, aa 1-157 (Fig.  2a) . Sequence alignment of the two peptides revealed a matched sequence 116 KAWGKSILFA 125 that is highly conserved in WNV and JEV strains ( Supplementary Fig.  S1 , available in JGV Online). However, 16NS1 did not recognize two overlapping peptides, NS1 (102-118) and NS1 (124-141), and 8NS1, a control mAb lacked reactivity with any of the peptides (Fig. 2a) . To confirm the 16NS1 peptide epitope, the DNA sequence coding for 116 KAWGKSILFA 125 was appended immediately upstream of the stop codon for the GST gene, expressed in bacteria, separated by SDS-PAGE, and subjected to Western blotting using 16NS1 mAb (Fig. 2b and c) . The 16NS1 mAb specifically reacted with the GST protein C-terminally fused with the 10 aa peptide 116 KAWGKSILFA 125 , but not with the GST protein alone (Fig. 2c, lanes 2 and 3) . Furthermore, the 16NS1 mAb showed no reactivity against GST fused with 119 GKSILF 124 , and the corresponding core LX1 sequence 113 IGWKAWG 119 from JEV and WNV that was characterized by a DENV complex-specific mAb against NS1 (Fig. 2c, lanes 4 and 5) (Falconar, 2007; Falconar et al., 1994) . These data establish that the 116 KAWGKSILFA 125 region is a novel epitope of the flavivirus NS1 protein recognized by the cross-reactive 16NS1 mAb.
To more rigorously define the 16NS1 mAb epitope, we performed fine epitope mapping using mutagenesis and yeast surface display analysis. Since the 16NS1 mAb lacks cross-reactivity with DENV-2 (Chung et al., 2006b), we hypothesized that the absence of binding to DENV-2 NS1 could be due to non-conservative amino acid(s) in the corresponding 116 KAWGKSILFA 125 region of DENV-2, JEV and WNV (Fig. 2d) . To test this possibility, the nonconservative residue, Ile, at position 122 ( 122 I) was changed to Ala. Individual residues in the 116 KAWGKSILFA 125 region were also replaced with Ala to define other essential residue(s) for 16NS1 mAb binding. The mutant peptide sequences were fused to the C terminus of the GST protein, expressed in bacteria and analysed by Western blotting (Fig. 2e and data not shown) . Notably, 16NS1 completely lost its binding activity in Ala mutants of 118 W and 122 I (Fig. 2e, lanes 3 and 4) . Surprisingly, a reciprocal change of the non-conservative residue 122 K in DENV-2 to I was sufficient to confer the binding of 16NS1 to the mutated 116 KTWGKAIMLS 125 region of DENV-2 (Fig. 2e , lanes 5 and 6). To further confirm the importance of the 118 W and 122 I residues contributing to the immunoreactivity of 16NS1, mutant WNV NS1 genes encoding W118A and I122A mutant were constructed, displayed on the surface of yeast cells and evaluated for mAb binding as described previously (Oliphant et al., 2005; Shrestha et al., 2010) . The W118A and I122A substitution of WNV NS1 also abolished the binding of 16NS1 mAb (Fig. 2f) . In addition, complete loss of JEV NS1-binding activity of 16NS1 mAb with W118A and I122A mutant version was also observed (data not shown). In contrast, the W118A and I122A WNV NS1 mutants did not inhibit the binding of a control mAb, 14NS1 that localized to FR-III of WNV NS1, aa 236-352 ( Fig. 2f and I amino acids as key residues for 16NS1 epitope recognition. Given that multiple flaviviruses co-circulate in the same endemic area, the need for developing innovative approaches to cross-reactive vaccines and/or therapeutics has increased. The data presented here provide new information that could enhance strategies for developing therapeutics and vaccines against JEV, WNV and other severe flavivirus infections.
